Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Top

Special Interview with Journal Associate Editor Dr. Andrea Nicolini

Published on: 4 Aug 2022 Viewed: 99

On August 1, 2022, the Editorial Office of Journal of Cancer Metastasis and Treatment (JCMT) was very honored to interview journal Associate Editor Dr. Andrea Nicolini, an outstanding expert in breast and gastrointestinal cancer and their metastases, from Department of Internal Medicine, University of Pisa, Santa Chiara Hospital, Pisa, Italy.

In 2022, Dr. Nicolini published a high-quality paper “Prognostic factors and efficacy of GDP-R therapy in refractory/relapsed diffuse large B-cell lymphomas not eligible for high-dose therapy that was widely read and highly appreciated in JCMT and other trending papers. In response to the request of our readers, the Editorial Department of Journal of Cancer Metastasis and Treatment had an online interview with Dr. Nicolini on his experience and perspective. 

Here are the details of the interview:

Q1: Your group published a wonderful article entitled " Prognostic factors and efficacy of GDP-R therapy in refractory/relapsed diffuse large B-cell lymphomas not eligible for high-dose therapy" in JCMT, which evaluates the overall survival (OS) and time to treatment failure (TTF) in a cohort of relapsed/refractory diffuse large B-cell lymphomas (DLBCLs). Could you further introduce the impact of patients who accept refractory/relapsed DLBCLs treated with GDP-R?

Q2: In 2022, you published articles about Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. They influenced many young researchers. What suggestions do you have for young researchers devoted to this research?

Q3. As an outstanding expert in breast and gastrointestinal cancer and their metastases, what do you think are the challenges that you face in this field? What do you think of the current situation and future breakthrough therapy for the treatment of breast and gastrointestinal cancer and their metastases?

Q4. As the Associate Editor of JCMT, what are your plans and expectations for the future development of the journal?

Personal Introduction

Andrea Nicolini:

From 1975, Dr. Andrea Nicolini has became a clinical researcher at the Department of Internal Medicine, University of Pisa, and then Aggregate Professor. From 1980, in the Internal Medicine Unit, he took the responsibility to take care of oncological patients, mostly breast and colorectal cancer patients, these patients underwent intensive follow-up programs focused on the use of tumor markers for the early diagnosis of recurrences. Constant evaluation of these patients allowed continuous improvement and updating of the intensive follow-up programs. For many years, he also had the responsibility of adjuvant and salvage treatments for oncological patients. In 2014, he retired from the academy, however, he continues to take care of patients in an outpatient setting.

Research interest: malignant solid tumors, in particular breast cancer, colorectal cancer and their metastases, tumor markers, post-operative follow-up, physiopathology, immunology and immunotherapy of cancer, thyroid tumors.

Scientific publications: 430. Impact Factor, total: 294.754. Invited reviewer for many International Journals, such as Journal Ranking 2011. Member of Editorial or Advisory Board of International Journals: Biomedicine & Pharmacotherapy, IJMS, Cancers, Biomarkers in Medicine, Journal of Cancer Metastases and Treatment, The Scientific World Journal, Tumor Biology.

Respectfully Submitted by the Journal Editorial Office
Journal of Cancer Metastasis and Treatment


© 2016-2022 OAE Publishing Inc., except certain content provided by third parties